A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience
Authors
Kuhnl, A.Roddie, C.
Kirkwood, A. A.
Tholouli, E.
Menne, T.
Patel, Amit
Besley, C.
Chaganti, S.
Sanderson, R.
O'Reilly, M.
Norman, J.
Osborne, W.
Bloor, Adrian
Lugthart, S.
Malladi, R.
Patten, P. E. M.
Neill, L.
Martinez-Cibrian, N.
Kennedy, H.
Phillips, Elizabeth H
Jones, C.
Sharplin, K.
El-Sharkawi, D.
Latif, A. L.
Mathew, A.
Uttenthal, B.
Stewart, O.
Marzolini, M. A. V.
Townsend, W.
Cwynarski, K.
Ardeshna, K.
Ardavan, A.
Robinson, K.
Pagliuca, A.
Collins, G. P.
Johnson, R.
McMillan, A.
Affiliation
Department of Haematology, King's College Hospital, London, UK.Issue Date
2022
Metadata
Show full item recordAbstract
CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide results of a large national cohort of patients intended to be treated with CAR-T in the UK. Consecutive patients with r/r LBCL approved for CAR-T by the National CAR-T Clinical Panel between December 2018 and November 2020 across all UK CAR-T centres were included. 404/432 patients were approved [292 axicabtagene ciloleucel (axi-cel), 112 tisagenlecleucel (tisa-cel)], 300 (74%) received the cells. 110/300 (38.3%) patients achieved complete remission (CR) at 6 months (m). The overall response rate was 77% (52% CR) for axi-cel, 57% (44% CR) for tisa-cel. The 12-month progression-free survival was 41.8% (axi-cel) and 27.4% (tisa-cel). Median overall survival for the intention-to-treat population was 10.5 m, 16.2 m for infused patients. The incidence of grade ≥3 cytokine release syndrome and neurotoxicity were 7.6%/19.6% for axi-cel and 7.9%/3.9% for tisa-cel. This prospective RW population of CAR-T eligible patients offers important insights into the clinical benefit of CD19 CAR-T in LBCL in daily practice. Our results confirm long-term efficacy in patients receiving treatment similar to the pivotal trials, but highlight the significance of early CAR-T failure.Citation
Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, et al. A national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience. British Journal of Haematology. Wiley; 2022.Journal
British Journal of HaematologyDOI
10.1111/bjh.18209PubMed ID
35485402Additional Links
https://dx.doi.org/10.1111/bjh.18209Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.18209
Scopus Count
Collections
Related articles
- Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
- Authors: Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M
- Issue date: 2024 Jan
- Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
- Authors: Cummings Joyner AK, Snider JT, Wade SW, Wang ST, Buessing MG, Johnson S, Gergis U
- Issue date: 2022 Aug
- Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
- Authors: Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini MC, Kröger N
- Issue date: 2024 Jun
- Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven.
- Authors: Brijs J, Van Ham J, Dubois B, Sinap F, Vergote V, Dierickx D, Vandenberghe P
- Issue date: 2024 Aug
- Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
- Authors: Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, Ahmed N, Schachter L, Bharucha K, Dholaria BR, Schuster SJ, Perales MA, Bishop MR, Porter DL
- Issue date: 2022 Oct